Menu
My ERA Join ERA

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Suggestions
My Era Join ERA
Home | Sustainable Nephrology Task Force

Sustainable Nephrology Task Force


2 / 2 results found

{%TITLE%}
{%SMALL_TITLE%}
{%TITLE%}
{%SUMMARY_INFO%}
{%TITLE%}

{%BOTTOM_TEXT%}

{%TITLE%}
{%SMALL_TITLE%}

{%EXCERPT%}

{%BOTTOM_TEXT%}